Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2011 - 2026)

Neurocrine Biosciences' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $381.4 million for Q1 2026.

• Quarterly Long-Term Deferred Tax fell 23.63% year-over-year to $381.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $381.4 million (down 23.63% YoY) and the FY2025 annual result came in at $320.3 million, down 34.05% from the prior year.
• Long-Term Deferred Tax was $381.4 million for Q1 2026 at Neurocrine Biosciences, up from $320.3 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $536.8 million in Q2 2025 and bottomed at $305.9 million in Q4 2022.
• A 5-year average of $387.4 million and a median of $378.2 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 33.95% — and 2025, when it plunged 34.05%.
• Neurocrine Biosciences' Long-Term Deferred Tax stood at $305.9 million in 2022, then grew by 18.54% to $362.6 million in 2023, then soared by 33.95% to $485.7 million in 2024, then plunged by 34.05% to $320.3 million in 2025, then grew by 19.08% to $381.4 million in 2026.
• Business Quant data shows NBIX's Long-Term Deferred Tax at $381.4 million in Q1 2026, $320.3 million in Q4 2025, and $368.5 million in Q3 2025.